Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients.
An Acad Bras Cienc
; 94(4): e20210202, 2022.
Article
in English
| MEDLINE | ID: covidwho-2029823
ABSTRACT
BACKGROUND:
Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients.METHODS:
One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease.RESULTS:
The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Plasma
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
An Acad Bras Cienc
Year:
2022
Document Type:
Article
Affiliation country:
0001-3765202220210202
Similar
MEDLINE
...
LILACS
LIS